Health In Tech, Inc. Class A Common Stock (HIT) Stock Forecast & Price Target
Health In Tech, Inc. Class A Common Stock · NASDAQ
$1.07+0.01 (+0.94%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Health In Tech, Inc. Class A Common Stock, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 274% above the current $1.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.01 next quarter toward $0.14 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Health In Tech, Inc. Class A Common Stock.
As of Jul, 1 of 1 firms rate HIT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HIT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.03 – $0.00 · 3 analysts · -233% YoY
Next period, 3 analysts expect Health In Tech, Inc. Class A Common Stock to earn $-0.01 a share (range $-0.03 – $0.00), versus $0.01 a year earlier. Full-year consensus is $-0.06, growing to $0.14 the year after.
REVENUE · NEXT QUARTER
$12.7M
Range $11.3M – $15.4M · 3 analysts · +49% YoY
Revenue is expected to reach $12.7M (range $11.3M – $15.4M), +49.1% year-over-year. Full-year consensus is $46.8M, rising to $78.5M next year.
Top analysts covering Health In Tech, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HIT.
#1
George Sutton
Craig-Hallum · Rank #114
Buy
$4.00+273.8% to target
Overall win rate
36%
+ Follow
#2
Allen Klee
Maxim Group · Rank #380
Buy
$2.50+133.6% to target
Overall win rate
18%
+ Follow
HIT stock forecast FAQ
What is HIT's average 12-month price target?+
The 1 analysts with a live target average $4.00 for Health In Tech, Inc. Class A Common Stock over the next 12 months, ranging from a $4.00 high to a $4.00 low.
Is HIT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover HIT?+
1 analysts have an active rating on Health In Tech, Inc. Class A Common Stock, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering HIT?+
Among analysts who currently cover HIT, George Sutton of Craig-Hallum has the strongest overall Quantellect track record (Rank #114). Their current call is Buy with a $4.00 target.
What is Health In Tech, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.03 – $0.00) across 3 analysts. Full-year EPS is projected at $-0.06, rising to $0.14 the following year.
How much revenue is Health In Tech, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $12.7M (range $11.3M – $15.4M). Full-year revenue is projected at $46.8M, growing to $78.5M next year.
Have analysts been upgrading or downgrading HIT lately?+
As of Jul, 1 of 1 firms rate HIT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HIT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
